ARCHIVES

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

This article is from The Cancer Letter archive.

Vol. 28 No. 41 | November 8, 2002

Download PDF Visit The Full Archive

Related Articles

L.A. County Nears Crucial Decision On Construction Funds

January 7, 1977

Social Networks Influence Decision To Quit Smoking

May 30, 2008

NCI Cooperative Groups Begin Trial Of Individualized Rx For Breast Cancer

May 26, 2006

Senate Committee Schedules Hearing for FDA Acting Commissioner von Eschenbach.

July 28, 2006

Cell Phone Radiation Does Not Raise Child’s Risk of Tumors

August 26, 2011

Anidulafungin Safe And Well-Tolerated In Pediatric Patients With Neutropenia

November 26, 2004